German NITAG Shows Why Vaccine Policy Cannot Be Fully Standardised
National immunisation recommendations sit at the junction of biology, economics, logistics, and public trust. The recent analysis from Schaefer, Harder, Sandmann, and Wichmann uses the German National Immunisation Technical Advisory Group as a case example to argue a basic point in vaccine policy: identical clinical evidence can reasonably lead to different national decisions.
That is not a flaw in expert review. It is the logic of public health decision-making.
National Immunisation Technical Advisory Groups, or NITAGs, are designed to do more than grade vaccine efficacy. They assess safety, effectiveness, and immunogenicity, but they also have to judge whether a vaccine fits local epidemiology, delivers value for money, can be implemented in routine care, and aligns with social values in the country where it will be used. A vaccine can be highly protective in a trial and still occupy a different place in two national schedules if the burden of disease, delivery infrastructure, or willingness to pay differs.
Identical Clinical Data, Different National Decisions
The article places particular emphasis on the gap between context-free evidence and country-specific judgment. Clinical efficacy is portable; policy is not. A vaccine’s ability to prevent disease does not automatically tell policymakers how urgently it should be introduced, which age group should receive it first, or whether a national programme can absorb the operational cost of delivery.
A single sentence captures the central policy tension. The same evidence can support more than one defensible recommendation.
That reality matters most when governments are under pressure to move quickly toward harmonised schedules. The analysis points to several European Union policy developments, including EU-level joint clinical assessments under the new Health Technology Assessment regulation and non-binding recommendations from the European Centre for Disease Prevention and Control. Both reflect a desire to reduce duplication and promote alignment across countries. Yet the article argues that harmonisation has limits when the underlying public health contexts are not the same.
Different countries face different pathogen circulation patterns, different baseline immunisation coverage, different health system capacities, and different public expectations. Those differences alter the value proposition of the same vaccine. A country with higher disease burden may prioritise rapid introduction. Another may place more weight on cost-effectiveness or on the feasibility of delivering the vaccine through existing primary care pathways. A recommendation that looks inconsistent from a distance may be fully rational once local constraints are included.
Why Context Changes the Policy Meaning of Evidence
Vaccine recommendations are not decided in a vacuum. They are built on the interaction between evidence and setting. If local epidemiology suggests a lower expected disease burden, the absolute benefit of a programme shrinks even when relative efficacy remains strong. If delivery systems are strained, the gains shown in controlled trials may be harder to reproduce at scale. If social values in one country place a premium on protecting infants or preventing severe outcomes in a particular age group, that normative judgement can shift the preferred target population.
Cost-effectiveness adds another layer. A vaccine can be clinically effective and still fail a national threshold if prices, administration costs, or implementation expenses overwhelm expected health gains. Programmatic feasibility is equally concrete. Cold chain capacity, workforce availability, appointment infrastructure, and coverage of hard-to-reach populations all affect whether a recommendation is operationally realistic.
This is why purely supranational guidance cannot replace national deliberation. International coordination can standardise methods, reduce redundant appraisal work, and improve transparency, but it cannot erase differences in disease burden or public health priorities. The authors’ argument is not anti-collaboration. It is a warning against assuming that administrative efficiency and clinical uniformity are the same thing.
EU Harmonisation Has Limits in Immunisation Policy
European policy makers are clearly looking for ways to align vaccine assessment across borders. Shared clinical assessment could prevent repeated work and speed access. Non-binding regional recommendations may help countries compare evidence using a common structure. Those are useful goals.
Still, the article draws a firm boundary around what harmonisation can accomplish. A regional framework can inform national choices, but it cannot substitute for the final judgment that each country must make about its own immunisation programme. A recommendation made for a country with one epidemiologic profile, one health financing model, and one set of implementation constraints should not be treated as automatically transferable to another setting.
The public health stakes are real. Vaccine policy affects who is protected, when protection begins, how quickly uptake rises, and whether scarce resources are spent on interventions that deliver the greatest benefit locally. Standardisation can improve efficiency, but excessive standardisation risks flattening the very context that determines whether a programme succeeds.
National Advisory Groups Still Carry the Hardest Work
NITAGs remain central because they translate evidence into action. They must decide not only whether a vaccine works, but whether it should be introduced now, for whom, and under what conditions. That work depends on more than clinical trial data. It requires local surveillance, budget impact analysis, knowledge of delivery systems, and a structured way to incorporate societal preferences.
In practice, that means two countries can review the same vaccine dossier and reach different conclusions without either group acting irrationally. One may see urgent need. Another may see limited incremental benefit relative to other priorities. Both may be responding appropriately to their own populations.
The article therefore lands on a clear policy position: international collaboration should support national decision-making, not replace it. Shared evidence reviews, joint assessments, and regional advice can help countries move faster and more consistently. Yet the final recommendation must remain sensitive to local context if immunisation policy is to remain both equitable and effective.
The unresolved issue is not whether countries should cooperate. It is how far harmonisation can go before it starts to erase the epidemiologic and programmatic differences that make national recommendations meaningful in the first place.